BDXBECTON DICKINSON & CO

NYSE bd.com


$ 235.79 $ -0.11 (-0.05 %)    

Tuesday, 20-Aug-2024 09:40:22 EDT
QQQ $ 481.49 $ 0.19 (0.04 %)
DIA $ 408.83 $ -0.06 (-0.01 %)
SPY $ 559.97 $ 0.81 (0.14 %)
TLT $ 98.27 $ -0.03 (-0.03 %)
GLD $ 233.24 $ -0.48 (-0.21 %)
$ 235.9
$ 235.74
$ 235.43 x 100
$ 236.20 x 200
$ 235.47 - $ 236.15
$ 218.75 - $ 279.14
1,025,230
na
68.19B
$ 0.44
$ 48.26
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-01-2024 12-31-2023 10-Q
4 11-21-2023 09-30-2023 10-K
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-02-2023 12-31-2022 10-Q
8 11-22-2022 09-30-2022 10-K
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-03-2022 12-31-2021 10-Q
12 11-24-2021 09-30-2021 10-K
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-04-2021 12-31-2020 10-Q
16 11-25-2020 09-30-2020 10-K
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-06-2020 12-31-2019 10-Q
20 11-27-2019 09-30-2019 10-K
21 08-06-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-05-2019 12-31-2018 10-Q
24 11-21-2018 09-30-2018 10-K
25 08-02-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 02-06-2018 12-31-2017 10-Q
28 11-22-2017 09-30-2017 10-K
29 08-03-2017 06-30-2017 10-Q
30 05-02-2017 03-31-2017 10-Q
31 02-02-2017 12-31-2016 10-Q
32 11-23-2016 09-30-2016 10-K
33 08-04-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-05-2016 12-31-2015 10-Q
36 11-25-2015 09-30-2015 10-K
37 08-06-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 02-06-2015 12-31-2014 10-Q
40 11-26-2014 09-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 raymond-james-maintains-outperform-on-becton-dickinson-lowers-price-target-to-270

Raymond James analyst Jayson Bedford maintains Becton Dickinson (NYSE:BDX) with a Outperform and lowers the price target fro...

 becton-dickinson-q3-2024-adj-eps-350-beats-331-estimate-sales-4990b-miss-5076b-estimate

Becton, Dickinson (NYSE:BDX) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $3.31 ...

 stifel-maintains-buy-on-becton-dickinson-raises-price-target-to-280

Stifel analyst Rick Wise maintains Becton Dickinson (NYSE:BDX) with a Buy and raises the price target from $270 to $280.

Core News & Articles

The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnos...

 cdc-says-disruptions-in-availability-of-becton-dickinson-bactec-blood-culture-bottles-blood-culture-bottles-issuing-health-alert-network-to-inform-critical-shortage-of-becton-dickinson-bactec-blood-culture-media-bottles-becton-dickinson-bactec-shortage-has-potential-to-disrupt-patient-care-by-leading-to-delays-in-diagnosis-misdiagnosis-or-other-challenges

- Reuters

 insulin-device-maker-embecta-weighs-sale-after-70-share-decline-following-becton-dickinson-spin-off

Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The comp...

 unitedhealth-edwards-lifesciences-first-citizens-bank-and-more-cnbcs-final-trades

UnitedHealth Group was declared a "solid" healthcare company on CNBC. Cantor Fitzgerald analyst Sarah James maintains a...

 citigroup-maintains-neutral-on-becton-dickinson-lowers-price-target-to-255

Citigroup analyst Joanna Wiensch maintains Becton Dickinson (NYSE:BDX) with a Neutral and lowers the price target from $260 ...

 fda-says--aware-that-us-is-experiencing-interruptions-in-the-supply-of-bd-bactec-blood-culture-media-bottles-because-of-recent-supplier-issues

- Reuters

 becton-dickinson-says-it-has-surpassed-its-scope-1-and-2-science-based-greenhouse-gas-ghg-emissions-reduction-targets-for-fy-2023-by-5-percentage-points

 This furthers the company's progress toward its goal to reach net zero GHG emissions across its value chain by FY 2050

 evercore-isi-group-maintains-outperform-on-becton-dickinson-lowers-price-target-to-285

Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:BDX) with a Outperform and lowers the price target f...

 bd-bolsters-portfolio-with-42b-cash-deal-for-edwards-lifesciences-critical-care-group-details

BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION